Clinical activity of enzalutamide in docetaxel-naïve and docetaxel-pretreated patients with metastatic castration-resistant prostate cancer

BACKGROUND: Two randomized clinical trials have demonstrated a survival advantage with enzalutamide over placebo in both docetaxel (D)-pretreated and D-naïve metastatic castration-resistant prostate cancer (mCRPC) patients. Cross-resistance between androgen receptor-directed therapies and taxanes ha...

Full description

Saved in:
Bibliographic Details
Main Authors: Nadal, Rosa, Zhang, Zhe, Rahman, Hibba, Schweizer, Michael T., Denmeade, Samuel R., Paller, Channing J., Carducci, Michael A., Eisenberger, Mario A., Antonarakis, Emmanuel S.
Format: Artigo
Language:Inglês
Published: 2014
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4176523/
https://ncbi.nlm.nih.gov/pubmed/25176007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.22874
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items